2004, Number 2
PDF size: 188.41 Kb.
ABSTRACTBreast cancer is one of the primary tumors that most frequently produces bone metastases, for this reason it is important to identify and to treat localized disease before there is metastatic dissemination. Patients with a diagnosis and treatment for breast cancer in the Instituto Nacional de Cancerología were evaluated between January 1st to December 31, 2002 with a clinical suspicion of metastatic bone lesions that had had a Metastatic Bone Series (MBS) and a Bone Scan (BS) with a time interval between studies of less than 12 weeks. From 114 patients the MBS detected 71 patients (62.2%) with metastatic lesions compared to 101 patients (88.5%) detected with a BS. Obtaining a sensitivity of 66% and a specificity of 70%. The best diagnostic accuracy for metastatic bone lesions is obtained with the use of both BS and MBS, complementing the sensitivity of the BS with the specificity of the MBS.
Kakonen S, Mundy G, Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer Suppl 2003;97:834-39.
Colleoni M, O’Neill A, y cols. Identifying breast Cancer patients at high risk for bone metastases Cancer. 2000;18:3925-35.
Colleoni M, Goldhirsch A, Coates A, y cols. Bone metastases in breast Cancer: How to prevent? J Clin Oncol. 2001;19:2764-65.
Howes D, Debra M, Neville A, y cols. Occult metastases in patients with breast Cancer. Ann Surg Oncol. 2001;8:605-635.
Rodan G. The development and function of the skeleton and bone metastases. Cancer Suppl. 2003;97:726-32.
Bleckmann D, Bachman C, Bohuslavizki S, Comparison of fluorodeoxyglucose positron emission tomography and conventional diagnosis procedures for the detection of distant metastases in breast Cancer patients. Nucl Med. 2002;23:857-64.
Yuji N, Osman M, Wahl R. Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG. Cancer. 2003;28:302-07.
De vita V. Cáncer principios y práctica de oncología, 5 Ed., España: editorial Panamericana, 2000:2570-85.